Angiotensin-receptor blockers as therapy for mild-to-moderate hypertension-associated non-alcoholic steatohepatitis - Wikidata - wikimedia - TriplyDB

Angiotensin-receptor blockers as therapy for mild-to-moderate hypertension-associated non-alcoholic steatohepatitis

Angiotensin-receptor blockers as therapy for mild-to-moderate hypertension-associated non-alcoholic steatohepatitis

http://www.wikidata.org/entity/Q37122480

about

A Comprehensive Updated Review of Pharmaceutical and Nonpharmaceutical Treatment for NAFLD Management of non-alcoholic fatty liver disease in 2015 Endocrine causes of nonalcoholic fatty liver disease Nonalcoholic steatohepatitis: emerging targeted therapies to optimize treatment options Pathophysiology guided treatment of nonalcoholic steatohepatitis Treatment of nonalcoholic steatohepatitis in adults: present and future The Global Nonalcoholic Fatty Liver Disease Epidemic: What a Radiologist Needs to Know.Hepatic steatosis and Type 2 diabetes: current and future treatment considerations.Telmisartan and Insulin Resistance in HIV (TAILoR): protocol for a dose-ranging phase II randomised open-labelled trial of telmisartan as a strategy for the reduction of insulin resistance in HIV-positive individuals on combination antiretroviral th Non-alcoholic fatty liver disease: an emerging driving force in chronic kidney disease.Comparative efficacy of interventions on nonalcoholic fatty liver disease (NAFLD): A PRISMA-compliant systematic review and network meta-analysis.Non-alcoholic fatty liver disease (NAFLD): why you should care, when you should worry, what you should do.A randomised controlled trial of losartan as an anti-fibrotic agent in non-alcoholic steatohepatitis.IGFBPrP1 induces liver fibrosis by inducing hepatic stellate cell activation and hepatocyte apoptosis via Smad2/3 signaling.Evolving concepts in the pathogenesis of NASH: beyond steatosis and inflammation.Systematic review of the effect of telmisartan on insulin sensitivity in hypertensive patients with insulin resistance or diabetes.Management of nonalcoholic fatty liver disease: an evidence-based clinical practice review.Republished: Non-alcoholic fatty liver disease: a practical approach to treatment.Safety and impact on cardiovascular events of long-term multifactorial treatment in patients with metabolic syndrome and abnormal liver function tests: a post hoc analysis of the randomised ATTEMPT study The impact of concomitant medication use on patient eligibility for phase I cancer clinical trials.Focus on therapeutic strategies of nonalcoholic Fatty liver disease Effect of telmisartan on histological activity and fibrosis of non-alcoholic steatohepatitis: A 1-year randomized control trial.Management of Non-alcoholic Fatty Liver Disease and Steatohepatitis.Pleiotropic effects of angiotensin receptor blockers: addressing comorbidities by optimizing hypertension therapy.Treatment of non-alcoholic fatty liver disease with focus on emerging drugs.Current therapeutic strategies in non-alcoholic fatty liver disease.Insulin resistance in nonalcoholic steatohepatitis: necessary but not sufficient - death of a dogma from analysis of therapeutic studies?Nonalcoholic fatty liver disease and diabetes mellitus: pathogenesis and treatment.Mechanisms linking nonalcoholic fatty liver disease with coronary artery disease.Impact of current treatments on liver disease, glucose metabolism and cardiovascular risk in non-alcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis of randomised trials.Inflammation and fibrogenesis in steatohepatitis.Update on new aspects of the renin-angiotensin system in liver disease: clinical implications and new therapeutic options.Telmisartan or valsartan alone or in combination with hydrochlorothiazide: a review.Diagnosis and management of cardiovascular risk in nonalcoholic fatty liver disease.Non-alcoholic fatty liver disease following liver transplantation: a clinical review.Pharmacotherapy for Nonalcoholic Fatty Liver Disease.Lipid disorder and intrahepatic renin-angiotensin system activation synergistically contribute to non-alcoholic fatty liver disease.Pharmacological management of nonalcoholic fatty liver disease in type 2 diabetes.Inhibition of Glutaminyl Cyclases alleviates CCL2-mediated inflammation of non-alcoholic fatty liver disease in mice.Effects of telmisartan on improving leptin resistance and inhibiting hepatic fibrosis in rats with non-alcoholic fatty liver disease.

P2860

Q26752487-C01ABED6-7577-46B7-96FE-11188FBD5CFF Q26771148-0CE2D7DC-9CD4-47F4-AAA8-0F6A57E64C9C Q26780254-C45875DC-415C-4AFA-A888-1CF0E640FAA0 Q26796448-11FF00FB-D066-4379-AB63-D37EE854FE0E Q26827117-8A284687-DD8B-46CC-8ABD-ACA70912986A Q26852403-8FF3C471-6F7A-41A1-AE80-67AEE83BD0C6 Q27008277-2845CB77-0FEA-4A91-B211-5AF1797A6FB1 Q27691399-1A74A306-13DA-4DF6-9799-F82DA81CFB23 Q28610551-72B3E2C1-500B-4A41-A0B8-F9FB3AA6C4E8 Q30235846-34B95906-BE3B-4BD4-A9E2-B532F2BA7440 Q30248535-978EB825-2BA6-4BC5-9805-13CF0AD4BDE5 Q30401022-551AAAEE-81F9-44B3-A451-AA86A3D8C90A Q33574413-ED0DE28D-FBF2-451B-BFA1-891A0E56EA54 Q33718285-282FA3D6-81FE-498B-928A-582DF36FB917 Q33755829-CE031081-6543-44CF-9AC1-400BD3732940 Q33994970-4B04E333-CFFA-4D06-BB74-C78AE5961C6B Q34168532-9361AB83-E690-43D6-9583-87154FB480F9 Q35135556-93B93A00-E4A6-4770-A659-2B3342C7CEF6 Q35674320-3E1A71D4-E129-42D0-A2F0-2095B211F975 Q36210439-2D8481FA-43D2-4681-9AC1-6CA5CE496EF9 Q36413703-DB79241D-0B82-47A1-85BE-1FCBD069901C Q36606808-39A59064-B43A-4EBB-BCAB-E69BD50E2F3C Q37613264-34E88419-BC81-4D63-8E6F-C614CDB515D6 Q37826797-AF0EF768-7E4B-4A02-81E0-BBF79FD74A62 Q37847181-A6095AB4-7931-4004-B2C9-C3AC891A50F1 Q37859419-281BB06A-3BB6-48CB-8C98-E2ED98B3DF7A Q37863142-5F03AD63-0DE6-47E1-976C-BC32A8025E4A Q37873715-E764DFAC-C806-4DAF-BF85-836C76A530F5 Q37886792-473F1F21-81B1-4A4C-AE20-4B1F95C338D8 Q37978785-C81196B3-782B-48C2-9236-1D45018AD318 Q37981867-32E5413C-F734-4960-8CCD-3D0D67AE22C6 Q38006726-12D60D08-DF49-4463-B5C6-B7EC0DA726F8 Q38032314-6B0AD164-A898-4F83-89CE-90039A751918 Q38261236-F76F6A06-2762-4CE1-9892-43D954134691 Q38543105-C79DEA02-17B9-4417-BADF-3A6A5AABA818 Q38588344-FC26B025-B183-47A4-9CB5-AA98F70CA0BB Q38782387-6D1C3768-F906-4582-AD00-2B81327F9C92 Q39170225-46253ED0-BC15-4749-B3A0-48D192CF8C6F Q39170768-0BA564D6-15EB-444B-AAA6-79CF9CD857B0 Q41672157-62CDDB7F-FF0C-48F6-B324-82D3C339C8FE

P2860

Angiotensin-receptor blockers as therapy for mild-to-moderate hypertension-associated non-alcoholic steatohepatitis

http://www.wikidata.org/entity/Q37122480

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on February 2009

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Angiotensin-receptor blockers ...... non-alcoholic steatohepatitis

@en

Angiotensin-receptor blockers ...... non-alcoholic steatohepatitis.

@nl

type

label

Angiotensin-receptor blockers ...... non-alcoholic steatohepatitis

@en

Angiotensin-receptor blockers ...... non-alcoholic steatohepatitis.

@nl

prefLabel

Angiotensin-receptor blockers ...... non-alcoholic steatohepatitis

@en

Angiotensin-receptor blockers ...... non-alcoholic steatohepatitis.

@nl

P1433

Q37122480-C2ACB839-CCBA-4167-961C-2C1CCABB821B

P1476

Q37122480-D7ACF4A8-7DEB-45FB-9D02-78FCC894BB2A

P2093

Q37122480-37E94D88-12C2-420E-BB27-FBD284684ABD

Q37122480-3B987F95-8316-49C6-BE99-D718C07084D6

Q37122480-719C3E07-619C-49C6-908D-A2928F7E6576

Q37122480-C13208BC-1B24-4322-B1A8-34F242332ADA

Q37122480-F8133E6C-A633-4DED-978B-BB903CC189BD

P2860

Q37122480-02C0B3E2-2BA3-409E-9EC9-2E6CFB00FE6B

Q37122480-0CD014C4-46AE-4436-A995-C9A68042C5A0

Q37122480-0D272D59-9B39-4A67-8F0E-13FABA107247

Q37122480-1370F0A2-4665-4376-9FE0-16933EE5450B

Q37122480-1ABA0860-21F9-4E9A-B7C9-98764EFEE2B9

Q37122480-2313F8B1-1569-4417-A494-09F9D66A18E7

Q37122480-2525559F-C4F4-411E-9E90-250BFBC6F557

Q37122480-26284CE6-FB3A-4D59-A848-DD6E6A11463A

Q37122480-27A2FBDA-3C57-45D9-96D5-AA1124A9F10A

Q37122480-2CEAF417-EEB4-4969-9287-27EF9F670472

P304

Q37122480-32F2F9E4-7755-4815-8951-446C65671641

P31

Q37122480-8175D419-0E52-491D-A1A0-CD06A1471C3D

P356

Q37122480-CEAA5A0F-A361-46A0-A149-8013045DDF06

P407

Q37122480-EF4A398A-3B39-4C98-ACEA-A07ED959A01C

P433

Q37122480-6EE03B4E-EBD1-44E4-BD2C-EC946AF09CE6

P478

Q37122480-BD3C99E1-813C-4F46-BF39-356CFEE216FC

P577

Q37122480-E40C4FA0-D2B4-4CA9-BD8D-9C06F3348993

P698

Q37122480-34962A2C-DFBE-45F3-81A2-B333E46E1CB6

P921

Q37122480-155BC126-93CC-4258-AE1D-D84395BC15BE

Q37122480-2E034922-CDFE-4EEF-9CE7-FEFDF52883AC

P932

Q37122480-7089BD3D-AEB5-415B-BC02-7FB2BFFB6AC1

P356

P1433

World Journal of Gastroenterology

P1476

Angiotensin-receptor blockers ...... non-alcoholic steatohepatitis

@en

P2093

Eugen Florin Georgescu

http://www.w3.org/2001/XMLSchema#string

Laurentiu Mogoanta

http://www.w3.org/2001/XMLSchema#string

Liliana Vancica

http://www.w3.org/2001/XMLSchema#string

Mihaela Niculescu

http://www.w3.org/2001/XMLSchema#string

Reanina Ionescu

http://www.w3.org/2001/XMLSchema#string

P2860

Guidelines on the use of liver biopsy in clinical practice

A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9

Cellular and molecular mechanisms of fibrosis

Angiotensin-(1-7) is an endogenous ligand for the G protein-coupled receptor Mas

Homeostasis model assessment: insulin resistance and ?-cell function from fasting plasma glucose and insulin concentrations in man

Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)

Design and validation of a histological scoring system for nonalcoholic fatty liver disease

Cryptogenic cirrhosis: clinical characterization and risk factors for underlying disease.

Newly recognized components of the renin-angiotensin system: potential roles in cardiovascular and renal regulation.

P304

942-954

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3748/WJG.15.942

http://www.w3.org/2001/XMLSchema#string

P407

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

15

http://www.w3.org/2001/XMLSchema#string

P577

2009-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

19248193

http://www.w3.org/2001/XMLSchema#string

P921

Steatohepatitis

arterial hypertension

P932

2653406

http://www.w3.org/2001/XMLSchema#string